



# IMPUROSE-B 10/20

Rosuvastatin 10 mg / 20 mg + Bempedoic Acid 180 mg Tablets

# IMPUROSE-B 10/20

Rosuvastatin 10 mg / 20 mg + Bempedoic Acid 180 mg Tablets

# **BACKGROUND:**

The dual combination of Rosuvastatin and Bempedoic Acid offers a superior approach to lowering LDL cholesterol. This powerful combination addresses persistent cardiovascular risk in patients with elevated cholesterol levels, even when on maximally tolerated statin doses. Together, Rosuvastatin and Bempedoic Acid work in harmony to achieve robust lipid reduction. This synergy not only lowers LDL cholesterol more effectively but also helps reduce the risk of cardiovascular events associated with hyperlipidemia.

# **DESCRIPTION:**

**IMPUROSE-B 10/20**: Available as film coated tablet of Bempedoic acid 180 mg and Rosuvastatin 10 mg and 20 mg. This combination medication is used along with a proper diet and other medications to help lower "bad" cholesterol (such as LDL) in the blood.

### INDICATION:

As adjunct to diet and maximally tolerated statin therapy for patients with ASCVD and/or heterozygous familial hypercholesterolemia who require additional LDL-Clowering.

# **MECHANISM OF ACTION:**

#### Bempedoic Acid:

- ✓ Bempedoic acid is a once-daily, oral, first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor.
- ✓ Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence.

#### Rosuvastatin:

- √ Rosuvastatin is in a class of medications called HMG-CoA reductase inhibitors (statins).
- ✓ It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

## **DOSAGE AND ADMINISTRATION:**

IMPUROSE-B 10/20: The recommended dosage is one tablet a day orally with or without food or as directed by the doctor.

#### **REFERENCES:**

Clin Investig Arterioscler. 2021 May:33 Suppl 1:53-57
Clin Med Insights Cardiol. 2012; 6: 17-33
Am J Cardiol 2016; 117:1928-1933
Future Pharmacol. 2023, 3(2), 392-406

Scan for more Prescribing Information



#### La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: +91-79-6616-8998 / 26936656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

Call me on: \_\_\_\_\_\_

©2024 All rights reserved, La Renon Healthcare Private Limited